We also found that most organoids were sensitive to the Src inhibitor bosutinib, which typically treats chronic myelogenous leukemia by inhibiting Bcr-Abl tyrosine kinase. This evidence concerns the gene SRC and chronic myelogenous leukemia, BCR-ABL1 positive.